A Promising Trial Targets a Genetic Risk for Alzheimer’s
By Gina Kolata,
The New York Times
| 12. 05. 2022
In a bold attempt to stop the progress of some cases of Alzheimer’s disease, a group of researchers is trying something new — injecting a protective gene into patients’ brains.
The trial involved just five patients with a particular genetic risk for Alzheimer’s. They received a very low dose of the gene therapy — a test of safety, which the treatment passed. But the preliminary results, announced Friday during the Clinical Trials on Alzheimer’s Disease conference, showed that proteins from the added gene appeared in the patients’ spinal fluid, and levels in the brain of two markers of Alzheimer’s disease, tau and amyloid, fell. Those findings were promising enough to advance the clinical trial into its next phase.
Treatment of another five patients at a higher dose is underway, and the work, initially funded by the nonprofit Alzheimer’s Drug Discovery Foundation, is supported by Lexeo Therapeutics, a fledgling company founded by Dr. Ronald Crystal, who is also chairman of the department of genetic medicine at Weill Cornell Medicine in New York. The hope is to get a stronger response... see more
Related Articles
Gene therapy has been the next big thing in medicine for decades. Until recent years, the results were underwhelming. Now there are promising developments and real successes, but significant questions remain: Is it safe enough? How many people might benefit, and under what conditions? And, crucially, how much will gene therapies cost and who will pay?
It has been more than 50 years since gene therapy was formally proposed; more than 40 years since the first scandal; more than 30...
By Manuel Ansede, El País | 01.15.2023
The gene editing techniques that have revolutionized medicine since 2016 could also be used to treat common heart diseases, the number one cause of death in humans, according to a study published recently by one of the world’s leading scientists, ...
By CGS Staff
| 01.14.2023
Photo by Isabela Kronemberger on Unsplash
Throughout 2022, CGS worked to deepen and expand collaborations with advocates and scholars concerned about the social justice implications of a range of human biotechnologies, with a major focus on the alarming prospect of using genome editing in human reproduction. We also organized and sponsored public events; curated, analyzed, and commented on news related to human genetics and assisted reproduction, both in media outlets and in our own newsletter and social media; and conducted...
By Emily Sohn, Nature | 01.09.2023
Each day, around 350 people in the United States die from lung cancer. Many of those deaths could be prevented by screening with low-dose computed tomography (CT) scans. But scanning millions of people would produce millions of images, and there...
